fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Tranexamic acid

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry

Cyklokapron · DIN 02064405 · 500 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Cyklokapron · DIN 02064405 Manufacturer: Pfizer Canada Inc.; listing date 2013-04-30 Health Canada: Marketed since 2005-07-08 · brand CYKLOKAPRON 500 MG · ATC B02AA02 TRANEXAMIC ACID · form Tablet · route Oral · ingredients TRANEXAMIC ACID 500 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cyklokapron: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02064405)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02064405). DIN 02064405: Cyklokapron Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 201216003; group id 265; item number 0534; lccId None; manufacturer id PFI Source form: Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02064405 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18072
Interchangeable products
Gd-Tranexamic Acid · DIN 02409097 · $0.8071 Mar-Tranexamic Acid · DIN 02496232 · $0.8071 Tranexamic Acid · DIN 02519194 · $0.8071 Tranexamic Acid Tablets · DIN 02401231 · $0.8071
Shortage status: resolved shortage (ended May 18, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02064405
Shortage record checked October 6, 2026

Gd-Tranexamic Acid · DIN 02409097 · 500 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Gd-Tranexamic Acid · DIN 02409097 Manufacturer: Genmed, A Division of Pfizer Canada Inc.; listing date 2015-07-29 Health Canada: Marketed since 2014-03-07 · brand GD-TRANEXAMIC ACID · ATC B02AA02 TRANEXAMIC ACID · form Tablet · route Oral · ingredients TRANEXAMIC ACID 500 MG · company Genmed a division of pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Gd-Tranexamic Acid: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8071). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02409097)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02409097). DIN 02409097: Gd-Tranexamic Acid Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 201216003; group id 265; item number 0534; lccId None; manufacturer id GEM Source form: Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.8071; ministry $0.8071 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02409097 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89382
Interchangeable products
Cyklokapron · DIN 02064405 · not recorded Mar-Tranexamic Acid · DIN 02496232 · $0.8071 Tranexamic Acid · DIN 02519194 · $0.8071 Tranexamic Acid Tablets · DIN 02401231 · $0.8071
Shortage status: resolved shortage (ended August 13, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02409097
Shortage record checked October 6, 2026

Mar-Tranexamic Acid · DIN 02496232 · 500 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Mar-Tranexamic Acid · DIN 02496232 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2020-08-28 Health Canada: Marketed since 2020-06-04 · brand MAR-TRANEXAMIC ACID · ATC B02AA02 TRANEXAMIC ACID · form Tablet · route Oral · ingredients TRANEXAMIC ACID 500 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mar-Tranexamic Acid: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8071). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02496232)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02496232). DIN 02496232: Mar-Tranexamic Acid Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 201216003; group id 265; item number 0534; lccId None; manufacturer id MAR Source form: Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.8071; ministry $0.8071 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02496232 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98610
Interchangeable products
Cyklokapron · DIN 02064405 · not recorded Gd-Tranexamic Acid · DIN 02409097 · $0.8071 Tranexamic Acid · DIN 02519194 · $0.8071 Tranexamic Acid Tablets · DIN 02401231 · $0.8071
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02496232
Shortage record checked October 6, 2026

Tranexamic Acid · DIN 02519194 · 500 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Tranexamic Acid · DIN 02519194 Manufacturer: Jamp Pharma Corporation; listing date 2022-01-31 Health Canada: Marketed since 2022-02-23 · brand TRANEXAMIC ACID · ATC B02AA02 TRANEXAMIC ACID · form Tablet · route Oral · ingredients TRANEXAMIC ACID 500 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Tranexamic Acid: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8071). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02519194)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02519194). DIN 02519194: Tranexamic Acid Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 201216003; group id 265; item number 0534; lccId None; manufacturer id JPC Source form: Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.8071; ministry $0.8071 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02519194 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100846
Interchangeable products
Cyklokapron · DIN 02064405 · not recorded Gd-Tranexamic Acid · DIN 02409097 · $0.8071 Mar-Tranexamic Acid · DIN 02496232 · $0.8071 Tranexamic Acid Tablets · DIN 02401231 · $0.8071
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519194
Shortage record checked October 6, 2026

Tranexamic Acid Tablets · DIN 02401231 · 500 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Tranexamic Acid Tablets · DIN 02401231 Manufacturer: Sterimax Inc.; listing date 2013-04-30 Health Canada: Marketed since 2013-02-13 · brand TRANEXAMIC ACID TABLETS · ATC B02AA02 TRANEXAMIC ACID · form Tablet · route Oral · ingredients TRANEXAMIC ACID 500 MG · company Sterimax inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Tranexamic Acid Tablets: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8071). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02401231)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02401231). DIN 02401231: Tranexamic Acid Tablets Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 201216003; group id 265; item number 0534; lccId None; manufacturer id STE Source form: Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.8071; ministry $0.8071 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02401231 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88596
Interchangeable products
Cyklokapron · DIN 02064405 · not recorded Gd-Tranexamic Acid · DIN 02409097 · $0.8071 Mar-Tranexamic Acid · DIN 02496232 · $0.8071 Tranexamic Acid · DIN 02519194 · $0.8071
Shortage status: resolved shortage (ended August 27, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02401231
Shortage record checked October 6, 2026
Other drugs in the same formulary class (20:12:16 Hemostatics) and how they are covered
No products matched this class search: “20:12:16”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 20:12:04 Direct Factor Xa Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS CYKLOKAPRON® (tranexamic acid) is indicated for:  Hereditary angioneurotic oedema.  Increased local fibrinolysis when the diagnosis is indicative of hyperfibrinolysis, as with conization of the cervix, dental extraction in patients with coagulopathies (in conjunction with antihaemophilic factor) epistaxis, hyphaema, and menorrhagia (hypermenorrhea). 1.1 Pediatrics Based on the data submitted and reviewed by Health Canada, the safety and efficacy of CYKLOKAPRON in pediatric patients has been established for use in hereditary angioneurotic oedema and increased local fibrinolysis when the diagnosis is indicative of hyperfibrinolysis. Specific data is available for surgical patients undergoing cardiac and orthopedic surgeries. Therefore, Health Canada has authorized CYKLOKAPRON in these indications for pediatric use. For menorrhagia (hypermenorrhea), limited data are available to Health Canada. Clinical experience with CYKLOKAPRON in menorrhagic (hypermenorrhea) children under 18 years of age is not available. Therefore, Health Canada has not authorized CYKLOKAPRON for this indication for pediatric use. 1.2 Geriatrics Clinical studies … https://pdf.hres.ca/dpd_pm/00063720.PDF PM date: DEC 05, 1995 Source product: CYKLOKAPRON 500 MG; DIN 02064405; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Cyklokapron, Gd-Tranexamic Acid, Mar-Tranexamic Acid, Tranexamic Acid, Tranexamic Acid Tablets: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026